EXICURE, INC. Proceeds from Sale of Productive Assets
EXICURE, INC. (XCUR) reported Proceeds from Sale of Productive Assets of $800.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2026-03-25
- EXICURE, INC. proceeds from sale of productive assets for the quarter ending 2025-12-31 was $0.00.
- EXICURE, INC. proceeds from sale of productive assets for fiscal 2025 was $800.00K.
| Period end | Proceeds from Sale of Productive Assets 1 month | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 9 month | Proceeds from Sale of Productive Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $800.00K 10-K · filed 2026-03-25 | ||
| 2025-09-30 | $800.00K 10-Q · filed 2025-11-07 | |||
| 2024-12-31 | $400.00K 10-K · filed 2025-03-18 | |||
| 2024-10-31 | $550.00K 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $150.00K 10-K · filed 2026-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |